Tag archives : Patients

  The European Medicines Agency’s (EMA) has recently granted marketing authorisation for the medicinal product  »Deferasirox Mylan », intended for the treatment of chronic iron overload due to blood transfusions in patients with β-thalassaemia major, non-transfusion-dependent thalassaemia syndromes and other anaemias. The manufacturer of this medicinal product is Mylan S.A.S.  »Deferasirox Mylan » will be ...

  Victoria Gray, 34-year-old mother-of-four, has volunteered to be the first American to have their genes edited with the controversial CRISPR technology to treat her SickleCell disease (SCD). For the first time, doctors in the U.S. have used the powerful gene-editing technique CRISPR to try to treat a patient with a ...

World Hepatitis Day (WHD) takes places every year on 28 July bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change. According to the World Health Organization (WHO), Viral hepatitis B and C affect 325 million people ...

This section is dedicated to alpha (α-) thalassaemia. THE MAJOR ALPHA (α-) THALASSAEMIAS ARE: HbH disease α-thalassaemia Hydrops Foetalis (=Hb Bart’s Hydrops Foetalis) Many diseases in humans are caused by abnormalities in the blood and these are categorized according to the component of the blood which is affected: white cell ...